News | November 11, 2013

Quality of Life Improves Following Stenting in Patients With Peripheral Artery Disease

Study released at Vascular Interventional Advances scientific conference

stents peripheral clinical triady study S.M.A.R.T. nitinol stent cordis
November 11, 2013 — Researchers at Saint Luke’s Mid America Heart Institute led a study that showed marked, long-term improvement in health status in patients suffering from peripheral artery (PAD) treated with the SMART nitinol self-expandable stent. Cordis Corp., manufacturer of the SMART Stent, sponsored the study.
 
David Safley, M.D., interventional cardiologist and lead investigator for the study, presented the findings at the annual Vascular Interventional Advances (VIVA) conference in Las Vegas. Study authors also included Elizabeth Magnuson, Sc.D., Haiyan Li, M.S., and David Cohen, M.D., M.Sc. director, cardiovascular research at Saint Luke's Mid America Heart Institute and professor, University of Missouri-Kansas City School of Medicine.
 
"One of the main goals of treating lower-extremity peripheral artery disease is symptom relief and improved health status," said Safley. "Although there have been substantial advances in device-based therapy in recent years, there is little data evaluating the impact of these treatments on patient-reported outcomes. In addition, most previous studies have focused on only short-term changes, so we wanted to see whether and to what extent any early benefits of revascularization were maintained."
 
The study used data from the STROLL (SMART Vascular Stent Systems in the Treatment of Obstructive Superficial Femoral Artery Disease) Trial to measure the degree and extent of meaningful improvements in both symptoms and quality of life in patients with superficial femoral artery (SFA) disease in the peripheral arteries treated with the SMART Stent.
 
A total of 250 patients were enrolled at 39 U.S. centers with a baseline health status that was substantially impaired. Health status was assessed at one, six, 12, 24 and 36 months using generic and peripheral artery-specific questionnaires. At one month follow-up, there was significant improvement on virtually all measurement scales. These early benefits were sustained through three-year follow up with only minimal attenuation over time.
 
"These findings demonstrate that among patients with symptomatic superficial femoral artery disease, opening the artery using the SMART nitinol self-expandable stent system provides clinically meaningful improvements in health status and quality of life that are maintained for at least three years," said Safley.
 
For more information: www.vivapvd.com, www.cordis.com

Related Content

BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Overlay Init